Skip to content

Evaluation of montelukast efficacy on clinical and FEV1/PEFR improvement in acute basthma attack

Evaluation of montelukast efficacy on clinical and FEV1/PEFR improvement in acute basthma attack

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015092215446N5
Enrollment
80
Registered
2015-12-27
Start date
2015-06-27
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute attack asthma. Asthma

Interventions

Intervention 1: Intervention Group: (N Salbutamol 2.5 mg + N Ipratropium 0.5 mg ) *3 times every 20 min. + 2 tabulate Montolocast 5 mg at 0 min. chew. Intervention 2: Control Group: (N Salbutamol 2.
Treatment - Drugs
Placebo
Intervention Group: (N Salbutamol 2.5 mg + N Ipratropium 0.5 mg ) *3 times every 20 min. + 2 tabulate Montolocast 5 mg at 0 min. chew.
Control Group: (N Salbutamol 2.5 mg + N Ipratropium 0.5 mg ) *3 times every 20 min. + 2 tabulate Placebo 5 mg at 0 min. chew.Total Patient at 0, 30, 60, 90,150min. After starting the intervention th

Sponsors

Vice chanceller for research, Ahvaz Jundishapur University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: age above 18 years old; documented asthmatic patients with spiropmetry. Exclusion criteria: no response to therapy; use of epinephrine or MgSO4 or IPPV during treatment; patient refuse from continue of treament; lung diseases like ILD; cigarrete smoking.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Clinical state. Timepoint: Before intervention, 30, 60, 90, 150 minutes after intervention. Method of measurement: Base on alert status, talking, wizing, use of respiratory mu.;Forced Expiratory Volum in First Secend (FEV1). Timepoint: Before intervention, 30, 60, 90, 150 minutes after intervention. Method of measurement: Mililiter with use of Peak Flow Meter.;Peak Expiratory Flow Rate(PEFR). Timepoint: Before intervention, 30, 60, 90, 150 minutes after intervention. Method of measurement: Mililiter with use of Peak Flow Meter.

Secondary

MeasureTime frame
Blood pressure. Timepoint: Before intervention, 30, 60, 90, 150 minutes after intervention. Method of measurement: mmHg.;Pulse Rate. Timepoint: Before intervention, 30, 60, 90, 150 minutes after intervention. Method of measurement: Rate/Minutes.;Respiratory Rate. Timepoint: Before intervention, 30, 60, 90, 150 minutes after intervention. Method of measurement: Rate/Minutes.;Saturation of arterial blood oxygen (SO2 %). Timepoint: Before intervention, 30, 60, 90, 150minutes after intervention. Method of measurement: Pulse Oximetry.;Pulsus Paradox. Timepoint: Before intervention, 30, 60, 90, 150 minutes after intervention. Method of measurement: 10 mmHg reduction of blood pressure during inspiration.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hasan Motamed

Ahvaz Golestan Hospital

Hasan_motamed@yahoo.com+98 61 3374 3079

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026